Literature DB >> 22047582

Hemophilia A induced by ipilimumab.

Julie Delyon, Christine Mateus, Thierry Lambert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22047582     DOI： 10.1056/NEJMc1110923

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  26 in total

1.  Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.

Authors:  Douglas B Johnson; Debra L Friedman; Elizabeth Berry; Ilka Decker; Fei Ye; Shilin Zhao; Alicia K Morgans; Igor Puzanov; Jeffrey A Sosman; Christine M Lovly
Journal:  Cancer Immunol Res       Date:  2015-02-03       Impact factor: 11.151

2.  Novel immune checkpoint blocker approved for the treatment of advanced melanoma.

Authors:  Lorenzo Galluzzi; Guido Kroemer; Alexander Eggermont
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

3.  Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.

Authors:  Chris Fellner
Journal:  P T       Date:  2012-09

Review 4.  Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.

Authors:  Lisa A Kottschade
Journal:  Curr Oncol Rep       Date:  2018-03-06       Impact factor: 5.075

Review 5.  Managing the skin toxicities from new melanoma drugs.

Authors:  John C Mavropoulos; Timothy S Wang
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 6.  Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.

Authors:  Petros Fessas; Lucia A Possamai; James Clark; Ella Daniels; Cathrin Gudd; Benjamin H Mullish; James L Alexander; David J Pinato
Journal:  Immunology       Date:  2019-11-19       Impact factor: 7.397

Review 7.  Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Aurélien Marabelle; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

8.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

Review 9.  Ipilimumab and its toxicities: a multidisciplinary approach.

Authors:  Leslie A Fecher; Sanjiv S Agarwala; F Stephen Hodi; Jeffrey S Weber
Journal:  Oncologist       Date:  2013-06-17

Review 10.  Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.

Authors:  Celine Boutros; Ahmad Tarhini; Emilie Routier; Olivier Lambotte; Francois Leroy Ladurie; Franck Carbonnel; Hassane Izzeddine; Aurelien Marabelle; Stephane Champiat; Armandine Berdelou; Emilie Lanoy; Matthieu Texier; Cristina Libenciuc; Alexander M M Eggermont; Jean-Charles Soria; Christine Mateus; Caroline Robert
Journal:  Nat Rev Clin Oncol       Date:  2016-05-04       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.